Peripheral blood stem cell mobilization from healthy donors

Özkan, Melda Cömert; Şahin, Fahri; Saydam, Güray

doi:10.1016/j.transci.2015.05.008

Cited by 21 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the use of corticosteroids in these immunocompromised patients implies an increased susceptibility to infections and graft rejection due to donor T-cell suppression. [20][21][22][23] In the current analysis, the use of peripheral blood grafts was an independent factor predictive for CRS development following haplo-HSCT. Different studies showed similar results.…”

Section: Discussionmentioning

confidence: 63%

“…Cumulative incidence (CI) of neutrophil engraftment at day +30 was 96% (95% CI, 92-100) achieved in a median of 17 days (range [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] and CI of platelet engraftment at day +100 was 94% (95% CI, 90-98) in a median of 29 days (range 15-226). CI of achievement of complete donor chimerism at day +100 was 93% (95% CI, 89.8-100).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide

Solán

Landete

Bailén

et al. 2020

Hematological Oncology

View full text Add to dashboard Cite

Cytokine release syndrome (CRS) is a systemic inflammatory response with aberrant immune activation and immune hyperstimulation, that leads to increased cytokine levels and inflammation. CRS has been described after antibody and cellular-based therapies. The use of posttransplant cyclophosphamide (PTCy) as graft-vs-host disease (GVHD) prophylaxis in haploidentical hematopoietic stem cell transplantation (haplo-HSCT) has led to the extension of allogeneic HSCT to patients without HLA-identical donors. Furthermore, PTCy has also been introduced in matched and unrelated donor HSCT. However, description of incidence and clinical impact of CRS on outcomes in these patients is scarce. We retrospectively analyzed 107 consecutive haplo-HSCT and 39 HLA-identical HSCT with PTCy from 2010 to 2017 in our institution. We used published CRS criteria to identify 76% and 14% of patients who developed CRS after haplo-HSCT and HLA-identical HSCT, respectively. Most patients presented CRS grades 1 and 2. Only one patient from the whole series presented grade 3 CRS and required tocilizumab therapy. The use of peripheral blood stem cells (PBSC), as well as total nucleated cells infused were associated with an increased risk of CRS. Patients who presented CRS developed grade II-IV acute GVHD more frequently than those who did not (60% vs 28.6% respectively, P = .012). The development of CRS was not significantly associated with nonrelapse mortality or overall survival. CRS is a frequent complication after PBSC haploidentical T-repleted HSCT, but significantly less frequent after HLA-identical HSCT. Most cases are mild. Prompt identification allows adequate management of severe forms. K E Y W O R D S cyclophosphamide, cytokine release syndrome, haploidentical stem cell transplantation, hematopoietic stem cell transplantation 1 | INTRODUCTION Cytokine release syndrome (CRS) is a systemic inflammatory response that occurs as a result of high-level immune activation. With the extended use of inmune-based therapies CRS has been increasingly recognized. 1 However, the pathophysiology of CRS is still incompletely understood. CRS is triggered by the massive release of IFN-γ by activated Tcells and / or tumor cells after the administration of antibody-based therapies, nonprotein-based cancer drugs such as oxaliplatin and lenalidomide and, recently, the new T-cell engaging immunotherapies including bispecific antibody constructs and chimeric antigen receptor (CAR) T cells. IFN-γ causes activation of different immune cells especially macrophages. Activated macrophages produce a cascade Jose Luis Díez-Martín and Mi Kwon contributed equally to this study.

show abstract

Section: Discussionmentioning

confidence: 63%

Section: Resultsmentioning

confidence: 99%

Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide

Solán

Landete

Bailén

et al. 2020

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…It can be performed using automated or semi automated devices [6]. Patients are generally mobilized after granulocyte-colony stimulating factor (G-CSF) alone or with plerixafor, or chemotherapy plus G-CSF [7,8]. For successful mobilization, age, diagnosis, stage of disease, type of chemotherapy and radiotherapy, the amount of peripheral CD34?…”

Section: Introductionmentioning

confidence: 99%

A Comparison of Fresenius Com.Tec Cell and Spectra Optia Cell Separators for Autologous and Allogeneic Stem Cell Collections: Single Center Experience

Solmaz

Kahraman²,

Sevindik

et al. 2018

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Peripheral blood is the prefered source for hematopoietic stem cells for hematopoietic stem cell transplantation. The efficiency of peripheral blood stem cell (PBSC) collection can vary among devices. In this study we aimed to compare feasibility and effectivity of apheresis procedures of the different systems. Two apheresis systems [Com.Tec (Fresenius Healthcare) and Spectra Optia (Caridian BCT)] were used in our center for the collection of PBSCs for autologous and allogeneic transplantation. We retrospectively analysed 190 apheresis procedures performed in healthy donors and patients between June 2012 and November 2014 in Department of Hematology, Dokuz Eylul University. PBSCS were collected by Fresenius cell separator (64 procedure) or Spectra Optia cell separator (126 procedure). Mobilization treatments were G-CSF (26.8%), cyclophosphamide plus G-CSF (48.4%), prelixafor plus G-CSF (14.7%), ESHAP (10%) and others. Patient and donor characteristics (age,

show abstract

“…G-CSF is approved and is widely used for mobilizing autologous hematopoietic progenitor cells into the peripheral blood for the purpose of collection and allogeneic graft. 26,27 Similarly, a combination of etoposide, ifosfamide, and cisplatin was shown to promote a small mobilization of CD341 cells in cancer patients. 28 Thus, attempts were made to model the influence of the SoC therapy, EPO, and/or G-CSF on the CD341 cell production rate or mobilization rate using a time-varying covariate approach (in which the presence of comedication was associated with a proportional shift in the base rate) or using the dosing history in a KPD modeling approach.…”

Section: Discussionmentioning

confidence: 99%

Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer

Bihorel

Raddad

Fiedler‐Kelly

et al. 2017

CPT Pharmacom & Syst Pharma

View full text Add to dashboard Cite

The objectives of this study were to characterize the pharmacokinetics (PK) of LY2510924, a potent peptide antagonist of the CXCR4 receptor, after subcutaneous administration in patients with advanced cancer forms and quantify LY2510924 stimulatory effects on the mobilization of cells bearing the cluster of differentiation 34 (CD34) as an indirect reflection of the chemokine C‐X‐C motif ligand 12/CXCR4 axis inhibition. LY2510924 PK were best characterized by a two‐compartment model with first‐order absorption and dose‐dependent clearance predicting steady state after three daily doses and little accumulation (accumulation ratio <1.17). The dynamics of CD34+ cell counts were best characterized with a precursor model with reversible transfer from the precursor to the central compartment and LY2510924‐driven stimulation of cell mobilization. Model‐based simulations show that once‐daily doses of 20 mg LY2510924 produce maximum CD34+ cell response and that peak effect typically occurs after three daily doses and slowly wanes over time.

show abstract

Peripheral blood stem cell mobilization from healthy donors

Cited by 21 publications

References 33 publications

Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide

Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide

A Comparison of Fresenius Com.Tec Cell and Spectra Optia Cell Separators for Autologous and Allogeneic Stem Cell Collections: Single Center Experience

Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer

Contact Info

Product

Resources

About